This Vectibix (panitumumab) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Amgen ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Busch sold 1,000 shares of Amgen. The total transaction amounted to $279,690. As of Wednesday ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals ...

Q1 2025 Earnings Call Transcript May 1, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $4.9, expectations were ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates ...

Amgen is well-positioned to deliver innovation ... Our innovative oncology portfolio, including BLINCYTO, IMDELLTRA, LUMAKRAS, Vectibix, KYPROLIS, Nplate and XGEVA grew 10% year-over-year ...

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients ...

Amgen Inc. (NASDAQ:AMGN – Free Report ... EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal ...